معرفی
Dr. Kelly E. Dunn is a Professor of Psychiatry and Neurobiology at the University of Maryland School of Medicine, and the Director of the Kahlert Institute for Addiction Medicine. With over two decades of experience, she focuses on opioid use disorder (OUD), pain management, and substance use epidemiology. Her research bridges clinical and translational studies, addressing OUD prevention, treatment innovation, and harm reduction strategies.
Education:
- B.A. in Psychology and Philosophy, SUNY Oswego (2002)
- M.S. in Applied Biopsychology, University of New Orleans (2005)
- Ph.D. in Human Behavioral Pharmacology/Experimental Psychology, University of Vermont (2009)
- Postdoctoral Training in Clinical Pharmacology, Johns Hopkins University (2011)
- M.B.A. in Healthcare Management, Johns Hopkins Carey School of Business (2019)
Research Interests: Dr. Dunn’s work emphasizes OUD mechanisms, medication development, and comorbid pain management. She explores fentanyl/xylazine interactions, withdrawal management, and policy interventions to address the opioid crisis. Her studies often integrate behavioral and pharmacological approaches, with a focus on vulnerable populations.
Key Contributions: She has authored over 150 peer-reviewed publications and secured >$20M in NIH grants. Her leadership roles include editorships of journals like Experimental and Clinical Psychopharmacology and Journal of Addiction Medicine, and presidencies of professional societies like the College on Problems of Drug Dependence.
Awards:
- Young Psychopharmacologist Award (APA Division 28)
- Joseph Cochin Young Investigator Award (CPDD)
- APA Fellow
Grants & Labs: Dr. Dunn leads NIH-funded projects on OUD pharmacotherapy and pain-OUD comorbidity. Her lab collaborates with institutions like Johns Hopkins and the National Institute on Drug Abuse (NIDA), focusing on clinical trials and real-world implementation of safer treatments.
